{"id":"NCT02928224","sponsor":"Pfizer","briefTitle":"Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","officialTitle":"A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-13","primaryCompletion":"2019-02-11","completion":"2022-11-10","firstPosted":"2016-10-10","resultsPosted":"2020-07-14","lastUpdate":"2023-12-21"},"enrollment":702,"design":{"allocation":"RANDOMIZED","model":"SEQUENTIAL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["BRAF V600E-mutant Metastatic Colorectal Cancer"],"interventions":[{"type":"DRUG","name":"Encorafenib","otherNames":[]},{"type":"DRUG","name":"Binimetinib","otherNames":[]},{"type":"DRUG","name":"Cetuximab","otherNames":[]},{"type":"DRUG","name":"Irinotecan","otherNames":[]},{"type":"DRUG","name":"Folinic Acid","otherNames":["FA"]},{"type":"DRUG","name":"5-Fluorouracil","otherNames":["5-FU"]}],"arms":[{"label":"Safety Lead-in, Triplet Arm","type":"EXPERIMENTAL"},{"label":"Doublet Arm","type":"EXPERIMENTAL"},{"label":"Control Arm","type":"ACTIVE_COMPARATOR"}],"summary":"This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib + cetuximab plus or minus binimetinib versus Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in patients with BRAFV600E mCRC whose disease has progressed after 1 or 2 prior regimens in the metastatic setting. The study contains a Safety Lead-in Phase in which the safety and tolerability of encorafenib + binimetinib + cetuximab will be assessed prior to the Phase 3 portion of the study.","primaryOutcome":{"measure":"(Safety Lead-in) Number of Participants With Dose-Limiting Toxicities (DLTs)","timeFrame":"Cycle 1 (up to 28 days)","effectByArm":[{"arm":"Combined Safety Lead-in (CSLI)","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":16},"locations":{"siteCount":418,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Czechia","Denmark","France","Germany","Hungary","Israel","Italy","Japan","Mexico","Netherlands","Norway","Poland","Russia","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["39313594","36653241","35654691","35653981","33503393","31566309","30892987"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=ARRAY-818-302"]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":37},"commonTop":["Diarrhoea","Nausea","Dermatitis acneiform","Vomiting","Fatigue"]}}